Posted by g_g_g_unit on November 2, 2009, at 15:12:09
i was sent this by an OCD researcher at Stanford. if anyone wants the full text, i can e-mail it to them.
"Page 1
Dextroamphetamine vs Caffeine Augmentation for OCD
Published online ahead of print: J Clin Psychiatry June 30, 2009: e1e6 (doi:10.4088/JCP.08m04605).
Available at
© Copyright 2009 Physicians Postgraduate Press, Inc.
e1
Double-Blind Study of
Dextroamphetamine Versus Caffeine Augmentation
for Treatment-Resistant Obsessive-Compulsive Disorder
Lorrin M. Koran, MD; Elias Aboujaoude, MD; and Nona N. Gamel, MSW
Introduction: Two small, double-blind,
placebo-controlled, single-dose, crossover studies
found dextroamphetamine (d-amphetamine) 30 mg
clearly superior to placebo in relieving symptoms
of obsessive-compulsive disorder (OCD). We con-
ducted a 5-week, double-blind, caffeine-controlled
study to test the hypothesis that d-amphetamine,
added after an adequate selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reup-take inhibitor (SNRI) trial, would be more effective than caffeine in reducing residual OCD symptoms of moderate or greater severity.Method: Between August 2006 and February
2008, we enrolled adults with DSM-IV OCD and a
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
score of ≥20 after ≥12 weeks of adequate treatment
with an SSRI or SNRI. Subjects were randomly as-
signed to double-blind d-amphetamine 30 mg/d or
caffeine 300 mg/d added to their SSRI/SNRI and
other medications. Responders (first week mean
Y-BOCS score decrease of ≥20%) entered the
studys 4-week double-blind extension phase.
Results: We enrolled 24 subjects, 11 women and
13 men, with a mean (SD) age of 40 (13.2) years and mean baseline Y-BOCS scores of 26.5 (4.1) for the d-amphetamine group (n=12) and 29.1 (4.0) for the caffeine group (n=12). At the end of week 1, six of 12 d-amphetamine subjects (50%) and 7 of 12 caffeine subjects (58%) were responders. At week 5, the responders mean Y-BOCS score decreases were, for the d-amphetamine group (last observation carried forward), 48% (range, 20%80%); and, for the
caffeine group, 55% (range, 27%89%). Obsessive-
compulsive disorder and depression improvement
were independent. The double-blind remained intact. No subject discontinued the study due to side effects.Conclusions: Larger, double-blind, placebo-
controlled trials of both d-amphetamine and caffeine augmentation are needed in OCD subjects inad-equately responsive to adequate doses of an SSRI or SNRI.
Trial Registration: clinicaltrials.gov Identifier:
NCT00363298
J Clin Psychiatry
© Copyright 2009 Physicians Postgraduate Press,
poster:g_g_g_unit
thread:924126
URL: http://www.dr-bob.org/babble/20091029/msgs/924126.html